Ventripoint Diagnostics Ltd. announced that Freiburg Hospital has chosen to adopt the VMS+ as its cardiac diagnostic tool. The University Medical Centre Freiburg im Breisgau, Germany, is notably one of the larger hospitals in Europe and is recognized as the supra-regional centre for the treatment of complicated heart disease. It treats approximately 90,000 inpatients and 897,000 outpatients annually.

The VMS+ will be utilized by the department of congenital heart defects and paediatric cardiology who treat 4,000+ children, youth, and young adults with congenital and acquired heart diseases each year. With the VMS+, the cardiac medical centre will be able to make its diagnostic and procedural decisions more efficiently and quickly, leading to better outcomes for patients. The VMS+ will serve as an adjunct to speed up decision- making in patient treatment and as an alternative to cardiac MRI when a patient is contraindicated.

Most importantly, VMS+ will be used to aid in diagnosis and in continuous monitoring of patients throughout their journey as performing a VMS+ study fits normal scanning workflows. The VMS+ will also be used to assist in the research of terminal heart failure and mechanical cardiovascular replacement and in pediatric drug trials for congenital heart defects. Sales, installation and support of the VMS+ in Europe is handled by Angiopro GmbH.

The cooperation between Ventripoint and Angiopro ensures optimal customer service, so that all VMS+ users can rely on intensive and timely support. Ventripoint is committed to elevating cardiac care through innovative products like the VMS+ and will continue to work with healthcare professionals and institutions to develop solutions that improve the patient care journey.